vs
Aclaris Therapeutics, Inc.（ACRS）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
Bio-Techne的季度营收约是Aclaris Therapeutics, Inc.的228.5倍（$295.9M vs $1.3M）。Bio-Techne净利率更高（12.8% vs -1528.6%，领先1541.4%）。Bio-Techne同比增速更快（-6.4% vs -85.9%）。过去两年Bio-Techne的营收复合增速更高（4.2% vs -26.5%）
Aclaris Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对免疫疾病、炎症性疾病和皮肤病的创新靶向疗法，核心管线覆盖斑秃、白癜风等未满足临床需求领域，致力于为全球相关患者提供新型治疗选择。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
ACRS vs TECH — 直观对比
营收规模更大
TECH
是对方的228.5倍
$1.3M
营收增速更快
TECH
高出79.5%
-85.9%
净利率更高
TECH
高出1541.4%
-1528.6%
两年增速更快
TECH
近两年复合增速
-26.5%
损益表 — Q4 2025 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3M | $295.9M |
| 净利润 | $-19.8M | $38.0M |
| 毛利率 | 58.9% | 64.6% |
| 营业利润率 | -1755.5% | 18.4% |
| 净利率 | -1528.6% | 12.8% |
| 营收同比 | -85.9% | -6.4% |
| 净利润同比 | 79.5% | 68.3% |
| 每股收益（稀释后） | $-0.16 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACRSTECH
| Q4 25 | $1.3M | $295.9M | ||
| Q3 25 | $3.3M | — | ||
| Q2 25 | $1.8M | $317.0M | ||
| Q1 25 | $1.5M | $316.2M | ||
| Q4 24 | $9.2M | $297.0M | ||
| Q3 24 | $4.3M | $289.5M | ||
| Q2 24 | $2.8M | $306.1M | ||
| Q1 24 | $2.4M | $303.4M |
净利润ACRSTECH
| Q4 25 | $-19.8M | $38.0M | ||
| Q3 25 | $-14.6M | — | ||
| Q2 25 | $-15.4M | $-17.7M | ||
| Q1 25 | $-15.1M | $22.6M | ||
| Q4 24 | $-96.6M | $34.9M | ||
| Q3 24 | $-7.6M | $33.6M | ||
| Q2 24 | $-11.0M | $40.6M | ||
| Q1 24 | $-16.9M | $49.1M |
毛利率ACRSTECH
| Q4 25 | 58.9% | 64.6% | ||
| Q3 25 | 83.7% | — | ||
| Q2 25 | 71.0% | 62.7% | ||
| Q1 25 | 65.2% | 67.9% | ||
| Q4 24 | 92.3% | 65.3% | ||
| Q3 24 | 85.0% | 63.2% | ||
| Q2 24 | 77.4% | 66.4% | ||
| Q1 24 | 66.3% | 67.4% |
营业利润率ACRSTECH
| Q4 25 | -1755.5% | 18.4% | ||
| Q3 25 | -519.8% | — | ||
| Q2 25 | -1035.9% | -7.5% | ||
| Q1 25 | -1242.9% | 12.2% | ||
| Q4 24 | -1082.3% | 16.0% | ||
| Q3 24 | -240.9% | 13.8% | ||
| Q2 24 | -464.7% | 15.0% | ||
| Q1 24 | -789.4% | 22.1% |
净利率ACRSTECH
| Q4 25 | -1528.6% | 12.8% | ||
| Q3 25 | -443.0% | — | ||
| Q2 25 | -868.3% | -5.6% | ||
| Q1 25 | -1036.8% | 7.1% | ||
| Q4 24 | -1048.3% | 11.7% | ||
| Q3 24 | -174.6% | 11.6% | ||
| Q2 24 | -397.2% | 13.3% | ||
| Q1 24 | -706.5% | 16.2% |
每股收益（稀释后）ACRSTECH
| Q4 25 | $-0.16 | $0.24 | ||
| Q3 25 | $-0.12 | — | ||
| Q2 25 | $-0.13 | $-0.11 | ||
| Q1 25 | $-0.12 | $0.14 | ||
| Q4 24 | $-1.21 | $0.22 | ||
| Q3 24 | $-0.11 | $0.21 | ||
| Q2 24 | $-0.15 | $0.26 | ||
| Q1 24 | $-0.24 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.0M | $172.9M |
| 总债务越低越好 | — | $260.0M |
| 股东权益账面价值 | $103.1M | $2.0B |
| 总资产 | $160.5M | $2.5B |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资ACRSTECH
| Q4 25 | $20.0M | $172.9M | ||
| Q3 25 | $25.3M | — | ||
| Q2 25 | $25.4M | $162.2M | ||
| Q1 25 | $30.4M | $140.7M | ||
| Q4 24 | $24.6M | $177.5M | ||
| Q3 24 | $47.7M | $187.5M | ||
| Q2 24 | $22.8M | $152.9M | ||
| Q1 24 | $35.8M | $145.3M |
总债务ACRSTECH
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
股东权益ACRSTECH
| Q4 25 | $103.1M | $2.0B | ||
| Q3 25 | $120.1M | — | ||
| Q2 25 | $131.7M | $1.9B | ||
| Q1 25 | $144.1M | $2.0B | ||
| Q4 24 | $155.6M | $2.1B | ||
| Q3 24 | $130.2M | $2.1B | ||
| Q2 24 | $133.8M | $2.1B | ||
| Q1 24 | $142.0M | $2.0B |
总资产ACRSTECH
| Q4 25 | $160.5M | $2.5B | ||
| Q3 25 | $175.5M | — | ||
| Q2 25 | $189.1M | $2.6B | ||
| Q1 25 | $198.1M | $2.6B | ||
| Q4 24 | $220.3M | $2.7B | ||
| Q3 24 | $182.4M | $2.7B | ||
| Q2 24 | $161.1M | $2.7B | ||
| Q1 24 | $174.1M | $2.7B |
负债/权益比ACRSTECH
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-13.1M | — |
| 自由现金流经营现金流 - 资本支出 | $-13.2M | — |
| 自由现金流率自由现金流/营收 | -1015.8% | — |
| 资本支出强度资本支出/营收 | 1.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-47.2M | — |
8季度趋势，按日历期对齐
经营现金流ACRSTECH
| Q4 25 | $-13.1M | — | ||
| Q3 25 | $-10.9M | — | ||
| Q2 25 | $-10.0M | $98.2M | ||
| Q1 25 | $-13.1M | $41.1M | ||
| Q4 24 | $-8.9M | $84.3M | ||
| Q3 24 | $22.0M | $63.9M | ||
| Q2 24 | $-12.3M | $75.5M | ||
| Q1 24 | $-20.8M | $81.0M |
自由现金流ACRSTECH
| Q4 25 | $-13.2M | — | ||
| Q3 25 | $-11.0M | — | ||
| Q2 25 | $-10.0M | $93.3M | ||
| Q1 25 | $-13.1M | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | $-12.3M | $57.5M | ||
| Q1 24 | $-20.9M | $64.5M |
自由现金流率ACRSTECH
| Q4 25 | -1015.8% | — | ||
| Q3 25 | -332.1% | — | ||
| Q2 25 | -563.5% | 29.4% | ||
| Q1 25 | -900.3% | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | -446.0% | 18.8% | ||
| Q1 24 | -873.6% | 21.3% |
资本支出强度ACRSTECH
| Q4 25 | 1.9% | — | ||
| Q3 25 | 0.7% | — | ||
| Q2 25 | 1.2% | 1.5% | ||
| Q1 25 | 3.0% | 3.2% | ||
| Q4 24 | 0.0% | 2.3% | ||
| Q3 24 | 0.0% | 3.2% | ||
| Q2 24 | 0.5% | 5.9% | ||
| Q1 24 | 5.6% | 5.4% |
现金转化率ACRSTECH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACRS
暂无分部数据
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
